A comprehensive view of AstraZeneca AB. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

INTERNATIONAL PATENT: ASTRAZENECA AB FILES APPLICATION FOR "SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER"

AstraZeneca and Daiichi Sankyo’s Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer; in Europe, about 531,000 breast cancer patients are diagnosed annually with around 141,000 deaths

Thermo Fisher Scientific partners with AstraZeneca to develop solid tissue and blood-based CDx test; test to identify patients with non-small cell lung cancer who may be eligible for treatment with Tagrisso osimertinib

Pieris Pharmaceuticals GmbH and AstraZeneca Submit United States Patent Application for Methods for Preventing or Treating Certain Disorders by Inhibiting Binding of IL-4 and/or IL-13 to Their Respective Receptors

AstraZeneca Listed a New Clinical Trial to Study Safety, Tolerability, and Pharmacokinetics of AZD0186

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count